![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Greenlights AngioDynamics’ NanoKnife Pilot Study
FDA Greenlights AngioDynamics’ NanoKnife Pilot Study
![Green_Light.gif](https://www.fdanews.com/ext/resources/test/Device_Images5/Green_Light.gif?t=1625610540&width=430)
The FDA has given the all clear for AngioDynamics to initiate its NanoKnife pilot study for the ablation of prostate cancer tissue in low-risk patients.
The prospective, non-randomized pilot study is small-scale, spanning six patients across up to three clinical sites. It’s meant to help design a pivotal U.S. clinical study that will support a premarket approval application for treatment of prostate cancer.
NanoKnife is a minimally invasive technique that has used irreversible electroporation to successfully treat focal prostate lesions.
“This pilot study represents the next step in our comprehensive approach to establish NanoKnife as a platform technology to treat numerous cancers and conditions,” said Brent Boucher, AngioDynamics’ senior vice president and general manager of oncology.
Upcoming Events
-
21Oct